SHP

"Shire jumped 60½p to 979p after it won approval earlier than expected from regulators in the United States to sell its Vyvanse hyperactivity drug – already licensed to children – to adults. This approval is likely to drive bid speculation. Pfizer and Astra-Zeneca, up 55p to £21.32 before results today, have already been rumoured to be considering the company."

The Times